A Promising Drug Target in Immunology: IGHD1-14 (Immunoglobulin Heavy Diversity 1-14 (Non-Functional))

Target Name: IGHD1-14

NCBI ID: G28508

IGHD1-14

Other Name(s): immunoglobulin heavy diversity 1-14 (non-functional) | IGHD114 | DM2 | Immunoglobulin heavy diversity 1-14 (non-functional)

A Promising Drug Target in Immunology: IGHD1-14 (Immunoglobulin Heavy Diversity 1-14 (Non-Functional))

Introduction

Immunoglobulin heavy chain (IGCH) genes are one of the largest families in the human proteome, encoding a diverse range of antibody subtypes and isoforms. The study of IGCHs has been greatly facilitated by the development of high-throughput techniques such as mass spectrometry, which allows for the rapid and accurate identification and quantification of individual IGCHs. One of the less well-studied IGCHs is IGHD1-14 (Immunoglobulin Heavy Diversity 1-14 (Non-Functional)). In this article, we will explore the potential drug targets and biomarkers associated with IGHD1-14 and highlight some of the recent progress in the study of this protein.

Drug Targets and Biomarkers for IGHD1-14

IGHD1-14 is a 14-kDa protein that is expressed in various tissues and cells, including B cells, macrophages, and cancer cells. It is one of the highly variable IGCHs, characterized by its diverse subtypes and isoforms. IGHD1-14 has been shown to play a critical role in several cellular processes, including immune responses, inflammation, and tissue repair. Therefore, it is a promising drug target in immunology.

One of the potential drug targets for IGHD1-14 is its role in immune cell function. IGHD1-14 has been shown to regulate the development and function of T cells, B cells, and natural killer cells, which are crucial for the immune response. In addition, IGHD1-14 has been shown to play a role in the regulation of inflammation and tissue repair. Therefore, drugs that can modulate IGHD1-14 function could be useful for treating a variety of immune-related diseases, including autoimmune disorders, cancer , and infections.

Another potential drug target for IGHD1-14 is its role in cancer progression. IGHD1-14 has been shown to be overexpressed in various types of cancer, including breast, lung, and colorectal cancer. In addition, IGHD1-14 has been shown to play a role in the development of cancer stem cells. Therefore, drugs that can inhibit IGHD1-14 function could be useful for treating cancer.

Biomarkers for IGHD1-14

IGHD1-14 is a protein that has been studied extensively using various techniques, including mass spectrometry, to identify its subtypes and isoforms. In addition, IGHD1-14 has been shown to have several potential biomarkers, including its ability to bind to antibodies and its ability to undergo conformational changes in response to different stimuli.

One of the most promising biomarkers for IGHD1-14 is its ability to bind to antibodies. IGHD1-14 has been shown to form a monomeric complex with various antibodies, including anti-IgG antibodies, which can modulate its function. Therefore, drugs that can Interfering with IGHD1-14 binding to antibodies could be useful for treating autoimmune disorders.

Another promising biomarker for IGHD1-14 is its ability to undergo conformational changes in response to different stimuli. IGHD1-14 has been shown to undergo a variety of conformational changes in response to different stimuli, including changes in its stability, localization, and activity. Therefore, drugs that can modulate IGHD1-14

Protein Name: Immunoglobulin Heavy Diversity 1-14 (non-functional)

The "IGHD1-14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHD1-14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets